BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9685512)

  • 21. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
    Hassager C; Jensen LT; Pødenphant J; Thomsen K; Christiansen C
    Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
    Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
    Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
    Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
    J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.
    Scariano JK; Glew RH; Bou-Serhal CE; Clemens JD; Garry PJ; Baumgartner RN
    Bone; 1998 Nov; 23(5):471-7. PubMed ID: 9823455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients.
    Maeno Y; Inaba M; Okuno S; Yamakawa T; Ishimura E; Nishizawa Y
    Clin Chem; 2005 Dec; 51(12):2312-7. PubMed ID: 16223890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
    Clemens JD; Herrick MV; Singer FR; Eyre DR
    Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
    Ravn P; Hosking D; Thompson D; Cizza G; Wasnich RD; McClung M; Yates AJ; Bjarnason NH; Christiansen C
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2363-8. PubMed ID: 10404804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prednisolone Effects on Urine Cross-Linked N-Telopeptides of Type I Collagen (Ntx) Diurnal Rhythms in Children.
    Wolthers OD; Heuck C
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):158-161. PubMed ID: 29366431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
    Bettica P; Bevilacqua M; Vago T; Masino M; Cucinotta E; Norbiato G
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women.
    Wasnich RD; Ross PD; Thompson DE; Cizza G; Yates AJ
    Osteoporos Int; 1999; 9(5):455-60. PubMed ID: 10550466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
    Pedrazzoni M; Alfano FS; Gatti C; Fantuzzi M; Girasole G; Campanini C; Basini G; Passeri M
    Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in bone resorption after menopause in Japanese women with normal or low bone mineral density: quantitation of urinary cross-linked N-telopeptides.
    Taguchi Y; Gorai I; Zhang MG; Chaki O; Nakayama M; Minaguchi H
    Calcif Tissue Int; 1998 May; 62(5):395-9. PubMed ID: 9541516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
    Boyce AM; Kelly MH; Brillante BA; Kushner H; Wientroub S; Riminucci M; Bianco P; Robey PG; Collins MT
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4133-40. PubMed ID: 25033066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis.
    Cryer B; Binkley N; Simonelli C; Lewiecki EM; Lanza F; Chen E; Petruschke RA; Mullen C; de Papp AE
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):127-36. PubMed ID: 16257815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P; Stancíková M; Letkovská A; Rovenský J
    Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
    Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
    J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
    Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
    J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.